13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE 13D Filed 2026-04-23 Event 2026-04-20 Intent: STRATEGIC SEC 0001193125-26-173780 →

Illumina Innovation Fund II, L.P. Alamar Biosciences, Inc. ALMR

Stake: 9.60% Shares: 5,856,536 CUSIP: 010911105 Class: Common Stock, par value $0.0001 per share
AI Analyst Brief conf: medium
Illumina's corporate venture arm filed a 13D on ALMR, a small-cap proteomics/biotech play, with no stated purpose disclosed — but the 13D form (vs. 13G) and 2 prior activist filings on this issuer in the last 90 days suggest this is not a passive hold; Illumina may be positioning for influence over a strategic outcome, potentially a takeout or technology partnership given the obvious synergy betwe

Item 4 — Purpose of Transaction

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Nicholas Naclerio is a member of the Issuer's board of directors. In addition, Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation policy, which became effective upon the effective date of the Registration Statement (as defined below). Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Other 13D/G Filings on Alamar Biosciences, Inc.

FiledFormFilerStakeShares
2026-04-23 SCHEDULE 13D Sands Capital Life Sciences Pulse Fund II, L.P. 6.30% 4,230,926 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →